Related references
Note: Only part of the references are listed.Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia
Arnon Nagler et al.
LEUKEMIA (2020)
Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report
Firoozeh Sahebi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Impact of KIR/HLA Incompatibilities on NK Cell Reconstitution and Clinical Outcome after T Cell-Replete Haploidentical Hematopoietic Stem Cell Transplantation with Posttransplant Cyclophosphamide
Catherine Willem et al.
JOURNAL OF IMMUNOLOGY (2019)
Monalizumab: inhibiting the novel immune checkpoint NKG2A
Thorbald van Hall et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Killer Cell Immunoglobulin-Like Receptor-Ligand Mismatch in Donor versus Recipient Direction Provides Better Graft-versus-Tumor Effect in Patients with Hematologic Malignancies Undergoing Allogeneic T Cell-Replete Haploidentical Transplantation Followed by Post-Transplant Cyclophosphamide
Anne Wanquet et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Safety and efficacy of haploidentical stem cell transplantation for multiple myeloma
Yao Chen et al.
BONE MARROW TRANSPLANTATION (2018)
Bone Marrow Versus Mobilized Peripheral Blood Stem Cells in Haploidentical Transplants Using Posttransplantation Cyclophosphamide
Annalisa Ruggeri et al.
CANCER (2018)
Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
Kerry S. Campbell et al.
FRONTIERS IN IMMUNOLOGY (2018)
NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications
Antonio Russo et al.
BLOOD (2018)
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide
Shannon R. McCurdy et al.
HAEMATOLOGICA (2017)
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide
Shannon R. McCurdy et al.
HAEMATOLOGICA (2017)
Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression
Massimo Giuliani et al.
ONCOTARGET (2017)
Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation
Stefan O. Ciurea et al.
BLOOD (2017)
Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis
Luca Castagna et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation
Mariana Bastos-Oreiro et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Hypoxia Induced Impairment of NK Cell Cytotoxicity against Multiple Myeloma Can Be Overcome by IL-2 Activation of the NK Cells
Subhashis Sarkar et al.
PLOS ONE (2013)
Natural killer cell activity in monoclonal gammopathies: Relation to disease activity
A. Österborg et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity
Daniela Pende et al.
BLOOD (2009)
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Leo Luznik et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation
Jumei Shi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells
Yasser M. El-Sherbiny et al.
CANCER RESEARCH (2007)
KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation
S Cooley et al.
BLOOD (2005)
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma
N Kröger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells
E Carbone et al.
BLOOD (2005)
Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors
S Giebel et al.
BLOOD (2003)
Anti-myeloma activity of natural killer lymphocytes
C Frohn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
Share Paper
